International Markets and Exelixis (EXEL): A Deep Dive for Investors
Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.
Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow
Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. EXEL's 2025 total revenue guidance is flat at $2.15B-$2.25B, although that doesn't model potential approval of cabozantinib for neuroendocrine tumors. EXEL's STELLAR-303 trial of zanzalintinib in metastatic colorectal cancer is expected to produce a result in H2'25, but the outcome is challenging to predict.
Exelixis, Inc. (EXEL) Q4 2024 Earnings Call Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs & Investor Relations Mike Morrissey - President & Chief Executive Officer Chris Senner - Chief Financial Officer PJ Haley - Executive Vice President, Commercial Amy Peterson - Chief Medical Officer Dana Aftab - Chief Scientific Officer Conference Call Participants Asthika Goonewardene - Truist Sean Laaman - Morgan Stanley David Lebowitz - Citi Gregory Renza - RBC Capital Markets Eva Fortea-Verdejo - Wells Fargo Jason Gerberry - Bank of America Securities Andy Hsieh - William Blair Yaron Werber - TD Cowen Peter Lawson - Barclays Stephen Willey - Stifel Ash Verma - UBS Sudan Loganathan - Stephens Operator Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2024 Financial Results Conference Call. My name is Sherry, and I'll be your operator for today.
Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.33 per share a year ago.
Exelixis Posts 63.7% Profit Surge
Exelixis (EXEL -2.06%), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise in both revenue and earnings. Announced on Feb. 11, 2025, the earnings release showcased Exelixis's performance amidst a challenging oncology landscape, with revenues surpassing year-over-year figures by 18.2%.
2 Stocks to Buy With Less Than $40
Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, investors can acquire shares of companies whose long-term prospects look exciting, and all for the price of a few breakfast items.
EXEL or TECH: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Exelixis (EXEL) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Here's Why Exelixis (EXEL) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
